Facts About Paniculoside I Revealed
All enrolled people who gained no less than one dose of zosuquidar or placebo during induction ended up monitored for the prevalence of adverse events (439 sufferers, 219 on zosuquidar and 210 on placebo). The commonest adverse functions were being related to the period of prolonged and considerable myelosuppression as is predicted with induction c